Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*-Reference-Cited by-同舟云学术

Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*

Published:2012-11-22 Issue:5 Volume:14 Page:284-292
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Stephan C¹,Hill A²,Sawyer W²,van Delft Y³,Moecklinghoff C⁴

Affiliation:

1. Johann Wolfgang Goethe University Hospital; Frankfurt; Germany

2. MetaVirology Ltd; London; UK

3. Janssen; Tilburg; The Netherlands

4. Janssen; Neuss; Germany

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Reference44 articles.

1. Ribaudo H Smith K Robbins G et al Race Differences in the efficacy of initial ART on HIV infection in randomized trials undertaken by ACTG 18 th Conference on Retroviruses and Opportunistic Infections 2011

2. Molina J Diaz-Menendez M Plana M Zamora J Lopez-Velez R Moreno S Very Late initiation of HAART impairs treatment response at 48 and 96 weeks: results from a meta-analysis of randomized trials 13 th European AIDS Conference 2012

3. Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy?;Wood;J Acquir Immune Defic Syndr,2005

4. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virological response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naïve patients;King;J Infect Dis,2004

5. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomized, non-inferiority trial;Cohen;Lancet,2011

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study;PLOS ONE;2024-02-23

2. Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate for adult patients with human immunodeficiency virus-1 in China: a retrospective real-world cohort study;Expert Review of Anti-infective Therapy;2023-12-06

3. Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV/AIDS;Medicine;2023-11-10

4. Comparison of dolutegravir+Lamivudine and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve patients infected with HIV: preliminary results from clinical practice;Expert Review of Anti-infective Therapy;2023-11-06

5. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study;2023-10-15